MediWound to Present at the 45th Annual TD Cowen Health Care Conference
MediWound (Nasdaq: MDWD), a specialist in enzymatic therapeutics for tissue repair, has announced its participation in the 45th Annual TD Cowen Health Care Conference in Boston. CEO Ofer Gonen will deliver a corporate overview on March 5, 2025, at 11:50 AM ET.
The presentation will be accessible through a live webcast, with registration available online. A replay will be made available on MediWound's website in the Events & Presentations section of the Investors area. The management team will also conduct one-on-one meetings with investors during the conference, which can be arranged through TD Cowen representatives.
MediWound (Nasdaq: MDWD), specialista in terapie enzimatiche per la riparazione dei tessuti, ha annunciato la sua partecipazione alla 45ª Conferenza Annuale TD Cowen sulla Salute a Boston. Il CEO Ofer Gonen presenterà una panoramica aziendale il 5 marzo 2025, alle 11:50 AM ET.
La presentazione sarà accessibile tramite un webcast dal vivo, con registrazione disponibile online. Una registrazione sarà resa disponibile sul sito web di MediWound nella sezione Eventi e Presentazioni dell'area Investitori. Il team di gestione condurrà anche incontri individuali con gli investitori durante la conferenza, che possono essere organizzati tramite i rappresentanti di TD Cowen.
MediWound (Nasdaq: MDWD), especialista en terapias enzimáticas para la reparación de tejidos, ha anunciado su participación en la 45ª Conferencia Anual de Salud TD Cowen en Boston. El CEO Ofer Gonen presentará una visión general de la empresa el 5 de marzo de 2025, a las 11:50 AM ET.
La presentación será accesible a través de una transmisión en vivo, con registro disponible en línea. Una repetición estará disponible en el sitio web de MediWound en la sección de Eventos y Presentaciones del área de Inversores. El equipo de gestión también llevará a cabo reuniones individuales con los inversores durante la conferencia, que se pueden organizar a través de los representantes de TD Cowen.
MediWound (Nasdaq: MDWD), 조직 복원을 위한 효소 치료 전문 기업이 제45회 TD Cowen 헬스케어 컨퍼런스에 참여한다고 발표했습니다. CEO 오퍼 고넨은 2025년 3월 5일, 오전 11시 50분 ET에 기업 개요를 발표할 예정입니다.
발표는 라이브 웹캐스트를 통해 접근 가능하며, 온라인 등록이 가능합니다. MediWound의 웹사이트에서 투자자 영역의 이벤트 및 발표 섹션에서 다시 보기 서비스를 제공할 예정입니다. 경영진 팀은 또한 컨퍼런스 동안 투자자와의 일대일 미팅을 진행하며, 이는 TD Cowen의 대표를 통해 조정할 수 있습니다.
MediWound (Nasdaq: MDWD), un spécialiste des thérapies enzymatiques pour la réparation des tissus, a annoncé sa participation à la 45e Conférence Annuelle TD Cowen sur la Santé à Boston. Le PDG Ofer Gonen présentera un aperçu de l'entreprise le 5 mars 2025 à 11h50 ET.
La présentation sera accessible via un webinaire en direct, avec une inscription disponible en ligne. Un replay sera disponible sur le site Web de MediWound dans la section Événements et Présentations de l'espace Investisseurs. L'équipe de direction organisera également des réunions individuelles avec les investisseurs pendant la conférence, qui pourront être arrangées par l'intermédiaire des représentants de TD Cowen.
MediWound (Nasdaq: MDWD), ein Spezialist für enzymatische Therapien zur Gewebereparatur, hat seine Teilnahme an der 45. jährlichen TD Cowen Gesundheitskonferenz in Boston angekündigt. CEO Ofer Gonen wird am 5. März 2025 um 11:50 Uhr ET eine Unternehmensübersicht präsentieren.
Die Präsentation wird über einen Live-Webcast zugänglich sein, eine Registrierung ist online möglich. Eine Aufzeichnung wird auf der Website von MediWound im Bereich Veranstaltungen und Präsentationen des Investorenbereichs verfügbar sein. Das Management-Team wird auch Einzelgespräche mit Investoren während der Konferenz führen, die über die Vertreter von TD Cowen organisiert werden können.
- None.
- None.
YAVNE, Israel, Feb. 24, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Officer Ofer Gonen will present a corporate overview at the upcoming 45th Annual TD Cowen Health Care Conference, taking place in Boston, MA on Wednesday, March 5, 2025, at 11:50 AM ET. To listen to the live webcast of the presentation, please register here.
A replay of the event will also be posted to MediWound’s website on the Events & Presentations page of the Investors section.
In addition, the MediWound management team will host one-on-one meetings during the conference. Interested investors are encouraged to contact their TD Cowen representative to schedule a meeting.
About MediWound
MediWound Ltd. (Nasdaq: MDWD) is a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of innovative biologics that enhance existing standards of care and improve patient experiences while reducing healthcare costs and unnecessary surgeries.
MediWound’s first drug, NexoBrid®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need for surgical interventions. Leveraging its proprietary enzymatic technology, MediWound is advancing EscharEx®, a promising candidate currently in Phase III development for the debridement of chronic wounds. Phase II clinical trials have shown EscharEx has distinct advantages over the currently available
For more information visit www.mediwound.com and follow us on LinkedIn.
| MediWound Contacts: | |
| Hani Luxenburg | Daniel Ferry |
| Chief Financial Officer | Managing Director |
| MediWound Ltd. | LifeSci Advisors, LLC |
| ir@mediwound.com | daniel@lifesciadvisors.com |
| Media Contact: |
| Ellie Hanson |
| FINN Partners for MediWound |
| ellie.hanson@finnpartners.com +1-929-588-2008 |
FAQ
When is MediWound (MDWD) presenting at the TD Cowen Health Care Conference 2025?
How can investors watch MediWound's (MDWD) presentation at the TD Cowen conference?
Can investors meet with MediWound (MDWD) management at the TD Cowen conference?
Who will be presenting for MediWound (MDWD) at the 2025 TD Cowen Health Care Conference?
